Platelet Aggregation Inhibitors
Thrombin is an enzyme in the blood that plays a key role in platelet formation during injury. While blood coagulation is essential for a surface wound, platelet activation underlies various pathological situations such as unstable angina pectoris, myocardial infarction and stroke. Thrombin is mediated by protease activated receptor-1 (PAR-1) which is expressed in the nervous system and in platelets. Once activated by thrombin, PAR-1 induces rapid and dramatic changes in cell morphology that is controlled by a series of localized ATP-dependent reactions. Technology: Researchers at the University of California have discovered specific creatine kinase inhibitors that inhibit thrombin-induced aggregation of platelets. These creatine kinase inhibitors could be used to treat a disease or disorder that is caused by pathological platelet aggregation.
Type of Offer:
« More Biotech Patents« More Pharmaceutical Patents